OptimizeRx (NASDAQ:OPRX) Releases Earnings Results, Beats Expectations By $0.17 EPS

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings results on Thursday. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.17, FiscalAI reports. The firm had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

OptimizeRx Trading Down 17.4%

OptimizeRx stock traded down $3.29 during trading on Friday, reaching $15.65. 1,013,794 shares of the company were exchanged, compared to its average volume of 372,301. The stock’s 50 day simple moving average is $18.87 and its two-hundred day simple moving average is $15.15. The company has a market capitalization of $290.54 million, a P/E ratio of -28.98 and a beta of 1.24. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $22.25.

Analyst Ratings Changes

Several analysts have commented on OPRX shares. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Stifel Nicolaus lifted their price target on shares of OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, August 8th. UBS Group set a $23.00 price objective on shares of OptimizeRx in a research report on Friday, October 10th. JMP Securities lifted their target price on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Finally, Roth Capital restated a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OptimizeRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.45.

Insider Transactions at OptimizeRx

In other news, CEO Stephen L. Silvestro sold 1,620 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer owned 188,916 shares of the company’s stock, valued at $3,542,175. This represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Patrick D. Spangler sold 11,120 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $17.49, for a total transaction of $194,488.80. Following the sale, the director owned 44,215 shares of the company’s stock, valued at $773,320.35. This represents a 20.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the 2nd quarter valued at $44,000. BNP Paribas Financial Markets raised its holdings in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the period. WINTON GROUP Ltd acquired a new position in OptimizeRx in the second quarter valued at about $286,000. Massar Capital Management LP purchased a new position in OptimizeRx during the second quarter worth about $297,000. Finally, American Century Companies Inc. boosted its stake in OptimizeRx by 52.5% during the second quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock worth $325,000 after buying an additional 8,286 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.